Detecting chronic traumatic encephalopathy (CTE) in living patients may soon be possible, according to preliminary data from a case series.
CTE, a neurodegenerative disease associated with repetitive head impacts from contact sports, currently can be diagnosed only at autopsy.
In a study of 21 former American football players who had donated their brains, however, blood levels of endogenously cleaved microtubule-binding region tau (eMTBR-tau) were higher in CTE-positive participants than in CTE-negative participants (β=1.61, 95% CI 0.51-2.70), reported Annalise Miner, a PhD candidate working on research under Michael Alosco, PhD, of Boston University, at the Clinical Trials on Alzheimer's Disease conference in Boston.
Concentrations of eMTBR-tau were highest in former players who also had Alzheimer's pathology at autopsy. Levels were intermediate in those with high-stage CTE who did not have Alzheimer's pathology, Miner said.
Players with high-stage CTE had higher eMTBR-tau concentrations than those with low-stage or no CTE, she added. Blood levels of phosphorylated tau 217 (p-tau217) were negative or intermediate in CTE cases, except in athletes with comorbid Alzheimer's disease.
The study was published simultaneously in JAMA.
"This is a game changer," co-author Alosco said in a statement. "We are still in the discovery phase and it's a small sample size, but if future studies validate these findings, this blood test will allow us to detect CTE with a high level of accuracy and open the doors to clinical trials and treatment."
The findings mirrored those of a case-control study led by Washington University in St. Louis, which was presented at a scientific meeting in Japan last week and also published in JAMA. That study showed plasma eMTBR-tau243 was elevated in late-stage CTE and some other tauopathies.
Both eMTBR-tau and eMTBR-tau243 measure the same key biological features, Miner noted. "Recent findings demonstrate a strong correlation between the immunoassay-derived eMTBR-tau and the mass spectrometry-derived eMTBR-tau243, supporting the biological relevance of this immunoassay," she said.
CTE remains a major diagnostic challenge, noted Carla Palleis, MD, and Günter Höglinger, MD, both of LMU University Hospital in Munich. "A biomarker capable of identifying CTE-associated tau pathology could improve selection of appropriate participants for research studies, facilitate clinicopathological studies, and ultimately support the evaluation of preventive and therapeutic interventions," they wrote in a JAMA editorial.
Detecting CTE at an early stage could be particularly valuable when clinical features seem nonspecific, the editorialists pointed out. Distinguishing traumatic encephalopathy syndrome -- a clinical syndrome associated with CTE -- from other causes of cognitive or behavioral symptoms can be difficult.
"Future studies should determine whether eMTBR-tau improves the ability of the criteria for traumatic encephalopathy syndrome to distinguish it and identify individuals with underlying CTE neuropathology, particularly in the presence of Alzheimer's disease copathology," Palleis and Höglinger wrote.
Over several years, eMTBR has emerged as blood biomarker for Alzheimer's disease. A 2025 study showed that eMTBR-tau243 was more strongly associated with tau tangle pathology in Alzheimer's than other established blood biomarkers. More recent work showed that blood tests measuring p-tau217 and eMTBR-tau243 improved triage and reduced overdiagnosis in people with asymptomatic Alzheimer's pathology.
Of the 21 former American football players included in the new study, 12 played professionally, seven played in college, and two played at the high school level. Eighteen former players had an autopsy diagnosis of CTE; of these, 16 had high-stage CTE (stage III or IV) and two had low-stage CTE (stage I or II). Five CTE-positive participants had intermediate or high Alzheimer's disease neuropathology.
Most participants were white and were diagnosed with traumatic encephalopathy syndrome cognitive impairment, Miner noted.
This work represents a first step toward a CTE biomarker framework, she observed. "By combining plasma eMTBR tau with Alzheimer's biomarkers like p-tau217, we may be able to capture complementary information that helps us move closer to diagnosing CTE during life," Miner said.
Disclosures
This study was supported by the National Institute of Neurological Disorders and Stroke and the National Institute on Aging.
Miner reported a patient pending. Alosco reported relationships with the NIH, the Department of Defense, Life Molecular Imaging, the Michael J. Fox Foundation, Oxford University Press, and having a patent pending.
Palleis reported holding a patent for treatment of human 4-repeat tauopathies and receiving honoraria from Teva Pharmaceuticals. Höglinger reported relationships with AbbVie, Biogen, Biohaven, Novartis, Roche, Sanofi, UCB, Alzprotect, Amylyx, Aprinoia Therapeutics, Asceneuron, Bayer, Bial, Epidarex Capital, Ferrer, Kyowa Kirin, Lundbeck, Retrotope, Servier, Takeda, Teva Pharmaceuticals, Bristol Myers Squibb, Pfizer, and Zambon.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.